Deutsche Bank Reiterates a 'Buy' on Regeneron Pharma (REGN); Fake Avastin - Our Take on Read Across to REGN's Eylea
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $803.48 -0.31%
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Deutsche Bank reiterates a 'Buy' on Regeneron Pharma (NASDAQ: REGN) price target of $140.00.
Deutsche analyst says, "According to Wall Street Journal report published today, 2/15/2012, Roche has issued a warning letter to doctors stating that a counterfeit version of Avastin has been found in the U.S. Reports of fake version of Avastin were previously seen in China...Though we do not know how widespread this issue is and what would be the exact impact of this on AMD practice, we believe doctors and patients may become cautious while using Avastin in AMD. Doctors in this setting are sensitive to safety issues. This could cause a short-term decline in Avastin use in AMD. However, long term use will probably remain intact."
"Any short-term switch of patients from Avastin will be shared between Eylea and Lucentis and will be upside to our estimates...Given the lack of visibility in this issue, we are not changing our numbers. However, we note that it is something investors should be aware of."
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $110.10 yesterday.
Deutsche analyst says, "According to Wall Street Journal report published today, 2/15/2012, Roche has issued a warning letter to doctors stating that a counterfeit version of Avastin has been found in the U.S. Reports of fake version of Avastin were previously seen in China...Though we do not know how widespread this issue is and what would be the exact impact of this on AMD practice, we believe doctors and patients may become cautious while using Avastin in AMD. Doctors in this setting are sensitive to safety issues. This could cause a short-term decline in Avastin use in AMD. However, long term use will probably remain intact."
"Any short-term switch of patients from Avastin will be shared between Eylea and Lucentis and will be upside to our estimates...Given the lack of visibility in this issue, we are not changing our numbers. However, we note that it is something investors should be aware of."
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $110.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
- BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Deutsche BankSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
